Ajanta Pharma Q1 FY26: Net Profit Rises 4% to ₹255 Crore on Strong Branded Generics Demand

delivered a solid performance in Q1 FY26, posting a 4% YoY increase in standalone net profit to ₹255 crore, up from ₹246 crore in the year‑ago quarter. Revenue rose to ₹1,303 crore from ₹1,145 crore, reflecting healthy demand across markets. Growth was driven by strong branded generics sales in India, Asia, and Africa, which rose 9% to ₹941 crore. Meanwhile, U.S. generics sales surged 36% YoY to ₹310 crore, contributing materially to overall performance. The company continues to benefit from its diversified presence in emerging markets and disciplined focus on high-growth therapeutic segments like ophthalmology, dermatology, and cardiology. Industry Perspective: Branded Generics Strength: Ajanta’s ability to drive double-digit traction in branded generics across multiple regions reflects strategic portfolio execution. U.S. Market Momentum: Strong recovery in U.S. generics points to improving approvals and product ramp-up—encouraging for long-term margin stability. Resilient Operating Model: Despite macroeconomic uncertainty, the operating leverage and regional diversification are cushioning revenue volatility. Takeaway: Ajanta Pharma continues to demonstrate controlled growth in a competitive pharma environment. With steady topline gains led by branded generics and recovering U.S. sales, its Q1 results reaffirm the company’s steady execution and strategic depth. Source: NDTV Profit No Recommendations